{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T09:24:15Z","timestamp":1763976255222,"version":"build-2065373602"},"reference-count":49,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T00:00:00Z","timestamp":1561680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004035","name":"Jordan University of Science and Technology","doi-asserted-by":"publisher","award":["20180113"],"award-info":[{"award-number":["20180113"]}],"id":[{"id":"10.13039\/501100004035","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Objectives: The aim of this study was to determine the incidence of metabolic syndrome in patients treated with second-generation antipsychotics (SGAs). Methods: In this retrospective study, we reviewed patients\u2019 electronic medical records (EMRs) of all patients who received one SGA for at least six months, excluding patients who were taking other medications that are associated with significant effect on metabolic syndrome. Relevant clinical information was collected prior to starting the SGA and after six months of continuous use of the same SGA. Results: A total of 91 patients were included in the study. The majority of patients (72%) were diagnosed with schizophrenia. After six months of taking the SGA, 44% of patients experienced elevated systolic pressure, 54.9% had elevated triglyceride, and 31.9% had impaired glucose levels (p value &lt; 0.05). Prior to initiating SGA therapy, 14.3% of patients had metabolic syndrome, while 37.4% had metabolic syndrome after six months of therapy, and it was more prominent in males compared to female patients (p value &lt; 0.05). Conclusion: This study found a strong correlation between SGA use and the appearance of metabolic alterations, such as weight gain, glucose intolerance, and increased triglyceride levels. These findings highlight the importance of assessing metabolic deregulations to minimize SGA associated metabolic abnormalities.<\/jats:p>","DOI":"10.3390\/medicina55070320","type":"journal-article","created":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T11:20:26Z","timestamp":1561720826000},"page":"320","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Effect of Long-Term Second-Generation Antipsychotics Use on the Metabolic Syndrome Parameters in Jordanian Population"],"prefix":"10.3390","volume":"55","author":[{"given":"Osama","family":"Abo Alrob","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy, Yarmouk University, Irbid 22110, Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayer","family":"Alazzam","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Jordan University of Science and Technology, Irbid 22110, Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2808-5099","authenticated-orcid":false,"given":"Karem","family":"Alzoubi","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Jordan University of Science and Technology, Irbid 22110, Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6163-8599","authenticated-orcid":false,"given":"Mohammad B.","family":"Nusair","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Yarmouk University, Irbid 22110, Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haneen","family":"Amawi","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Yarmouk University, Irbid 22110, Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reema","family":"Karasneh","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Yarmouk University, Irbid 22110, Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abeer","family":"Rababa\u2019h","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Jordan University of Science and Technology, Irbid 22110, Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Nammas","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Jordan University of Science and Technology, Irbid 22110, Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,6,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001). Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA, 285, 2486\u20132497.","DOI":"10.1001\/jama.285.19.2486"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4103\/2230-8210.91175","article-title":"Changing definitions of metabolic syndrome","volume":"16","author":"Mohan","year":"2012","journal-title":"Indian J. Endocrinol. Metab."},{"key":"ref_3","unstructured":"International Diabetes Federation (2006). The IDF consensus worldwide definition of the metabolic syndrome. IDF Commun., 1\u201323."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1177\/1074248416686187","article-title":"Metabolic syndrome: Clinical and policy implications of the new silent killer","volume":"22","author":"Sherling","year":"2017","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00592-011-0309-6","article-title":"Metabolic syndrome: Its history, mechanisms, and limitations","volume":"49","author":"Oda","year":"2012","journal-title":"Acta Diabetol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ecl.2013.09.009","article-title":"Metabolic syndrome","volume":"43","author":"Samson","year":"2014","journal-title":"Endocrin. Metabol. Clinics"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jacc.2013.05.064","article-title":"Prevalence and trends of Metabolic Syndrome in the adult US population, 1999\u20132010","volume":"62","author":"Harhay","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1161\/CIRCULATIONAHA.106.658336","article-title":"Metabolic syndrome: Is it a syndrome? does it matter?","volume":"115","author":"Kahn","year":"2007","journal-title":"Circulation"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00023210-200519001-00001","article-title":"Second-Generation (Atypical) Antipsychotics and Metabolic Effects","volume":"19","author":"Newcomer","year":"2005","journal-title":"CNS Drugs"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1192\/bjp.171.6.502","article-title":"Excess mortality of schizophrenia. A meta-analysis","volume":"171","author":"Brown","year":"1997","journal-title":"Br. J. Psychiatry"},{"key":"ref_11","first-page":"292","article-title":"Atypical Antipsychotics and Metabolic Syndrome in Patients with Schizophrenia: Risk Factors, Monitoring, and Healthcare Implications","volume":"4","author":"Riordan","year":"2011","journal-title":"Am. Heal. Drug Benefits"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s40264-016-0475-0","article-title":"The harms of antipsychotic drugs: Evidence from key studies","volume":"40","author":"Moore","year":"2017","journal-title":"Drug Safety"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.eurpsy.2010.09.011","article-title":"Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice","volume":"26","author":"Dobbelaere","year":"2011","journal-title":"Europ. Psy."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/XCE.0000000000000063","article-title":"Atypical antipsychotics and metabolic syndrome","volume":"4","author":"Lewczuk","year":"2015","journal-title":"Cardiovasc. Endocrinol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1016\/j.euroneuro.2006.06.003","article-title":"Differential metabolic effects of antipsychotic treatments","volume":"16","author":"Haupt","year":"2006","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.pharmthera.2010.04.008","article-title":"Potential mechanisms of atypical antipsychotic-induced metabolic derangement: Clues for understanding obesity and novel drug design","volume":"127","author":"Coccurello","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.amjmed.2008.04.017","article-title":"Acute Effects of Newer Antipsychotic Drugs on Glucose Metabolism","volume":"121","author":"Hasnain","year":"2008","journal-title":"Am. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/JCP.0b013e3181934462","article-title":"HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: A replication study","volume":"29","author":"Mulder","year":"2009","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/YIC.0b013e32833bc60d","article-title":"MTHFR genotype and differential evolution of metabolic parameters after initiation of a second generation antipsychotic: An observational study","volume":"25","author":"Moons","year":"2010","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1038\/tp.2011.68","article-title":"Cardiometabolic risk and the MTHFR C677T variant in children treated with second-generation antipsychotics","volume":"2","author":"Devlin","year":"2012","journal-title":"Transl. Psychiatry"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/sj.mp.4002066","article-title":"Atypical antipsychotic-induced metabolic side effects: Insights from receptor-binding profiles","volume":"13","author":"Nasrallah","year":"2008","journal-title":"Mol. Psychiatry"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia","volume":"353","author":"Davis","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care, 27, 596\u2013601.","DOI":"10.2337\/diacare.27.2.596"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.12669\/pjms.316.7714","article-title":"Alarming high prevalence of metabolic syndrome among Jordanian adults","volume":"31","author":"Obeidat","year":"2015","journal-title":"Pak. J. Med Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"375","DOI":"10.26719\/2010.16.4.375","article-title":"Metabolic syndrome in patients with hypertension attending a family practice clinic in Jordan","volume":"16","author":"Yasein","year":"2010","journal-title":"East. Mediterr. Heal. J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.amjcard.2008.02.096","article-title":"Comparison of Waist Circumference Versus Body Mass Index in Diagnosing Metabolic Syndrome and Identifying Apparently Healthy Subjects at Increased Risk of Cardiovascular Disease","volume":"102","author":"Ryan","year":"2008","journal-title":"Am. J. Cardiol."},{"key":"ref_27","unstructured":"World Health Organization (2019, January 19). Definition, diagnosis and classification of diabetes mellitus and its complications: Report of a WHO consultation.part 1, diagnosis and classification of diabetes mellitus. Available online: http:\/\/apps.who.int\/iris\/handle\/10665\/66040."},{"key":"ref_28","unstructured":"RxList (2019, June 27). Schizophrenia. Available online: https:\/\/www.rxlist.com\/schizophrenia\/article.htm."},{"key":"ref_29","first-page":"51","article-title":"Recommendations for lab monitoring of atypical antipsychotics","volume":"12","author":"Zeier","year":"2013","journal-title":"Curr. Psychiatr."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Chen, J., Huang, X.-F., Shao, R., Chen, C., and Deng, C. (2017). Molecular Mechanisms of Antipsychotic Drug-Induced Diabetes. Front. Mol. Neurosci., 11.","DOI":"10.3389\/fnins.2017.00643"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s40263-013-0115-5","article-title":"Second Generation Antipsychotic-Induced Type 2 Diabetes: A Role for the Muscarinic M3 Receptor","volume":"27","author":"Huang","year":"2013","journal-title":"CNS Drugs"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.2337\/diabetes.54.5.1552","article-title":"Inhibitory Effects of Antipsychotics on Carbachol-Enhanced Insulin Secretion From Perifused Rat Islets: Role of Muscarinic Antagonism in Antipsychotic-Induced Diabetes and Hyperglycemia","volume":"54","author":"Johnson","year":"2005","journal-title":"Diabetes"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/sj.mp.4001729","article-title":"Olanzapine impairs glycogen synthesis and insulin signaling in L6 skeletal muscle cells","volume":"10","author":"Engl","year":"2005","journal-title":"Mol. Psychiatry"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Larsen, J.R., Svensson, C.K., Vedtofte, L., Jakobsen, M.L., Jespersen, H.S., Jakobsen, M.I., Koyuncu, K., Schjerning, O., Nielsen, J., and Ekstr\u00f8m, C.T. (2018). High prevalence of prediabetes and metabolic abnormalities in overweight or obese schizophrenia patients treated with clozapine or olanzapine. CNS Spectr., 1\u201312.","DOI":"10.1017\/S1092852918001311"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/YIC.0b013e32832d6c18","article-title":"Risk of lipid abnormality with haloperidol, olanzapine, quetiapine, and risperidone in a Veterans Affairs population","volume":"24","author":"Duncan","year":"2009","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.schres.2010.10.029","article-title":"Increased Framingham 10-year risk of coronary heart disease in middle-aged and older patients with psychotic symptoms","volume":"125","author":"Jin","year":"2011","journal-title":"Schizophr. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.schres.2018.12.006","article-title":"The role of weight gain in explaining the effects of antipsychotic drugs on positive and negative symptoms: An analysis of the CATIE schizophrenia trial","volume":"206","author":"Bellavia","year":"2019","journal-title":"Schizophr. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.1038\/tp.2013.83","article-title":"Antipsychotics and the gut microbiome: olanzapine-induced metabolic dysfunction is attenuated by antibiotic administration in the rat","volume":"3","author":"Davey","year":"2013","journal-title":"Transl. Psychiatry"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.schres.2018.11.036","article-title":"Meta-analysis of ghrelin alterations in schizophrenia: Effects of olanzapine","volume":"206","author":"Goetz","year":"2019","journal-title":"Schizophr. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s12264-018-0323-6","article-title":"Pharmacogenetic Correlates of Antipsychotic-Induced Weight Gain in the Chinese Population","volume":"35","author":"Luo","year":"2019","journal-title":"Neurosci. Bull."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3928\/02793695-20180108-05","article-title":"Metabolic Side Effects in Patients Using Atypical Antipsychotic Medications During Hospitalization","volume":"56","author":"Arabaci","year":"2018","journal-title":"J. Psychosoc. Nurs. Ment. Heal. Serv."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"pii: 18m02299","DOI":"10.4088\/PCC.18m02299","article-title":"Acute Blood Pressure Changes Associated With Antipsychotic Administration to Psychiatric Inpatients","volume":"20","author":"Parks","year":"2018","journal-title":"Prim. Care Companion CNS Disord."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"81","DOI":"10.9740\/mhc.2017.03.081","article-title":"Cardiometabolic management in severe mental illness requiring an atypical antipsychotic","volume":"7","author":"Schmitz","year":"2018","journal-title":"Ment. Heal. Clin."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/hup.915","article-title":"Cardiac side effects of psychiatric drugs","volume":"23","author":"Mackin","year":"2008","journal-title":"Hum. Psychopharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"365","DOI":"10.9758\/cpn.2016.14.4.365","article-title":"Arterial Stiffness in Patients Taking Second-generation Antipsychotics","volume":"14","author":"Nacitarhan","year":"2016","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/jphp.12892","article-title":"Genetic polymorphisms of HTR2C, LEP and LEPR on metabolic syndromes in patients treated with atypical antipsychotic drugs","volume":"70","author":"Puangpetch","year":"2018","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/JCP.0000000000000770","article-title":"A Pilot Study of the Usefulness of a Single Olanzapine Plasma Concentration as an Indicator of Early Drug Effect in a Small Sample of First-Episode Psychosis Patients","volume":"37","author":"Zabala","year":"2017","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2174\/157488631002150515120209","article-title":"Prevalence of Cardiovascular and Metabolic Events in Patients Prescribed Clozapine: A Retrospective Observational, Clinical Cohort Study","volume":"10","author":"Hyde","year":"2015","journal-title":"Curr. Drug Saf."},{"key":"ref_49","first-page":"181","article-title":"Threats to Validity in Retrospective Studies","volume":"3","author":"Tofthagen","year":"2012","journal-title":"J. Adv. Pr. Oncol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/55\/7\/320\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:02:16Z","timestamp":1760187736000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/55\/7\/320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,28]]},"references-count":49,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,7]]}},"alternative-id":["medicina55070320"],"URL":"https:\/\/doi.org\/10.3390\/medicina55070320","relation":{},"ISSN":["1648-9144"],"issn-type":[{"type":"electronic","value":"1648-9144"}],"subject":[],"published":{"date-parts":[[2019,6,28]]}}}